Evidence map›Paper›PMID 34648678›Full record

ArticleJournal of the International AIDS Society2021

HIV PrEP is more than ART-lite: Longitudinal study of real-world PrEP services data identifies missing measures meaningful to HIV prevention programming.

Jason Bailey Reed, Prakriti Shrestha, Daniel Were, Tafadzwa Chakare, Jane Mutegi, Brian Wakhutu, Abednego Musau, Nyane Matebello Nonyana, Alice Christensen, Rupa Patel and 4 more

Abstract read
In one paragraph

Article in Journal of the International AIDS Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jason Bailey ReedJhpiego, Baltimore, Maryland, USA.ORCID 0000-0002-8001-1150
Prakriti ShresthaDepartment of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0003-2127-162X
Daniel WereJhpiego, Nairobi, Nairobi, Kenya.ORCID 0000-0002-6538-002X
Tafadzwa ChakareJhpiego, Maseru, Maseru, Lesotho.
Jane MutegiJhpiego, Nairobi, Nairobi, Kenya.
Brian WakhutuJhpiego, Nairobi, Nairobi, Kenya.
Abednego MusauJhpiego, Nairobi, Nairobi, Kenya.
Nyane Matebello NonyanaJhpiego, Maseru, Maseru, Lesotho.
Alice ChristensenJhpiego, Dar es Salaam, Tanzania.
Rupa PatelWashington University, St. Louis, Missouri, USA.ORCID 0000-0002-0329-7036
Jessica RodriguesAVAC, New York City, New York, USA.
Robyn EakleUSAID, Washington, DC, USA.
Kelly CurranJhpiego, Baltimore, Maryland, USA.
Diwakar MohanDepartment of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionEvidence indicates HIV oral pre-exposure prophylaxis (PrEP) is highly efficacious and effective. Substantial early discontinuation rates are reported by many programs, which may be misconstrued as program failure. However, PrEP use may be non-continuous and still effective, since HIV risk fluctuates. Real-world PrEP use phenomena, like restarting and cyclical use, and the temporal characteristics of these use patterns are not well described. The objective of our study was to characterize and identify predictors of use patterns observed in large PrEP scale-up programs in Africa.

methodsWe analysed demographic and clinical data routinely collected during client visits between 2017 and 2019 in three Jhpiego-supported programs in Kenya, Lesotho and Tanzania. We characterized duration on/off PrEP and, using ordinal regression, modelled the likelihood of spending additional time off and identified factors associated with increasing cycle number. The Andersen-Gill model was used to identify predictors of time to PrEP discontinuation. To analyse factors associated with a client's first return following initiation, we used a two-step Heckman probit.

resultsAmong 47,532 clients initiating PrEP, approximately half returned for follow-up. With each increase in cycle number, time off PrEP between use cycles decreased. The Heckman first-step model showed an increased probability of returning versus not by older age groups and among key and vulnerable population groups versus the general population; in the second-step model older age groups and key and vulnerable populations were less likely in Kenya, but more likely in Lesotho, to return on-time (refill) versus delayed (restarting).

conclusionsPrEP users frequently cycle on and off PrEP. Early discontinuation and delays in obtaining additional prescriptions were common, with broad predictive variability noted. Time off PrEP decreased with cycle number in all countries, suggesting normalization of use with experience. More nuanced measures of use are needed than exist for HIV treatment if effective use of PrEP is to be meaningfully measured. Providers should be equipped with measures and counselling messages that recognize non-continuous and cyclical use patterns so that clients are supported to align fluctuating risk and use, and can readily restart PrEP after stopping, in effect empowering them further to make their own prevention choices.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisAgedHumansKenyaLongitudinal StudiesAnti-HIV AgentsadherencecontinuationHIV pre-exposure prophylaxisretentionsub-Saharan Africa

Identifiers

PMID34648678
PMCPMC8516366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.